This work was also supported by the National Key Research and Development Program of China (2018YFA0507001, 2018YFA0507000, 2018YFA0508100), the National Natural Science Foundation of China grants 31770898 (G.S.), 31900895 (L.Y.) and 81872915 (M.-W.W.), the National Science and Technology Major Project Key New Drug Creation and Manufacturing Program of China (2018ZX09735-001) and China Postdoctoral Science Foundation (2017M622365)
, - L- , L- L-, -
Final Thoughts GLP-1 agonists represent an interesting and evolving area of research in autoimmune care, particularly due to their effects on metabolic health
The famous omega-6 fatty acid , the mother of all -6 fatty acids in our body
For people who already qualify for GLP-1 therapy because of diabetes or obesity especially cancer survivors the potential cancer benefits may become an additional factor in shared decision-making with their healthcare team
Optimize Hormones For many people, addressing: Thyroid function Testosterone levels Estrogen/progesterone balance can dramatically change their response to GLP-1 therapy